Literature DB >> 11781063

Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment.

Ulrike H M Ziegner1, Roger H Kobayashi, Charlotte Cunningham-Rundles, Teresa Español, Anders Fasth, Anna Huttenlocher, Paul Krogstad, Lars Marthinsen, Luigi D Notarangelo, Srdjan Pasic, Christian H L Rieger, Peter Rudge, Raman Sankar, Ann O Shigeoka, E Richard Stiehm, Kathleen E Sullivan, A David Webster, Hans D Ochs.   

Abstract

We have identified 14 patients with diverse primary immunodeficiencies who have developed progressive neurodegeneration of unknown etiology. All patients had received immunoglobulin replacement therapy for a mean duration of 6.5 years (range of 0.5-13.5 years) at the time of first neurological symptoms. Diagnostic tests of blood and cerebrospinal fluid analyses included chemistry, cultures, PCR for viral genomes, and cytology. In addition, neuroimaging and electrophysiologic studies were performed. Brain tissue histology (n = 5) revealed nonspecific encephalitis with microglial infiltration and neuronal loss. Twelve patients died 6 months to 15 years (median 4.3 years) after onset of neurologic findings. No evidence of any infectious disease that could have explained our patients' progressive encephalopathy was found either during their lifetimes or postmortem. These patients may have had an unusual manifestation of primary immunodeficiency diseases, an autoimmune reaction against neuronal tissue, a yet undefined infectious agent, or a complication of IVIG therapy. To help determine the etiology of this rare complication, an international surveillance system for primary immunodeficiency patients who develop progressive neurodegeneration of unknown cause is recommended. (c)2001 Elsevier Science.

Entities:  

Mesh:

Year:  2002        PMID: 11781063     DOI: 10.1006/clim.2001.5140

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  17 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Common variable immunodeficiency-associated myelitis: report of treatment with infliximab.

Authors:  N Kumar; J B Hagan; R S Abraham; A J Aksamit
Journal:  J Neurol       Date:  2008-07-21       Impact factor: 4.849

3.  Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia.

Authors:  Rolla F Abu-Arja; Leah R Chernin; Ghada Abusin; Jeffery Auletta; Linda Cabral; Rachel Egler; Hans D Ochs; Troy R Torgerson; Jesus Lopez-Guisa; Robert W Hostoffer; Haig Tcheurekdjian; Kenneth R Cooke
Journal:  Pediatr Blood Cancer       Date:  2015-04-20       Impact factor: 3.167

4.  Recurrent myelitis in common variable immunodeficiency successfully managed with high-dose subcutaneous immunoglobulin.

Authors:  Maria Giovanna Danieli; Lucia Pettinari; Lucia Marinangeli; Francesco Logullo
Journal:  BMJ Case Rep       Date:  2012-08-08

5.  X-linked agammaglobulinemia with hearing impairment, dystonia-parkinsonism, and progressive neurodegeneration.

Authors:  Aloysius Domingo; Thomas G P M Schmidt; Ela Barcelon; Marissa Lukban; Ana Westenberger; Christine Klein
Journal:  J Neurol       Date:  2014-10-01       Impact factor: 4.849

6.  Neurologic Complications of Common Variable Immunodeficiency.

Authors:  Jenna Thuc-Uyen Nguyen; Ari Green; Michael R Wilson; Joseph L DeRisi; Katherine Gundling
Journal:  J Clin Immunol       Date:  2016-10-04       Impact factor: 8.317

7.  Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

Authors:  M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2016-09-30       Impact factor: 10.793

8.  CD40 ligand deficiency: neurologic sequelae with radiographic correlation.

Authors:  Shrinivas Bishu; Deepak Madhavan; Phillip Perez; Lucy Civitello; Shuying Liu; Margaret Fessler; Steven M Holland; Ashish Jain; Maryland Pao
Journal:  Pediatr Neurol       Date:  2009-12       Impact factor: 3.372

Review 9.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Authors:  P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

Review 10.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.